Why did NXTC stock move up on 2026-08-10?
In plain English
No clear news behind the move — this looks driven by momentum rather than a specific catalyst.
What it means for you
Finished the day strong — closed near its highs on heavy volume. Risk level: moderate.
Where this comes from
Observed market data. The price, percentage move, open, close and volume above are end-of-day figures for 2026-08-10 from XNAS, not estimates.
No confirmed catalyst. The news feed returned no article for this ticker around this date. That does not mean nothing happened — only that we found nothing we can source, so we are not going to invent a reason.
Price history
274 daily closes through 2026-09-18. End-of-day data — not live prices.
Where NXTC sits in its 52-week range
Context for how far NXTC has moved over the past year — not a signal about where it goes next.
NXTC move history
Every other day we have recorded NXTC moving at least 15% on heavy volume. Dates, prices and volumes are end-of-day market data; the catalyst column links the news article that existed for that date, or says so when none did.
| Date | Move | Close | Volume | Catalyst |
|---|---|---|---|---|
| 2026-07-27 | +20.8% | $5.12 | 1.1M | No confirmed catalyst |
| 2026-07-14 | +201.8% | $6.58 | 111.5M | NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, |
About NextCure, Inc. Common Stock
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
NXTC — frequently asked
Why did NXTC stock move up on 2026-08-10?
No clear news behind the move — this looks driven by momentum rather than a specific catalyst. Finished the day strong — closed near its highs on heavy volume.
What is the NXTC stock price today?
The most recent close we hold for NextCure, Inc. Common Stock (NXTC) is $6.12 on 2026-09-18, which is more recent than the 2026-08-10 move described above. Trader Club publishes end-of-day prices, not live quotes, so check your broker for the current price.
What is NXTC's 52-week range?
Over the past year of daily closes, NXTC has ranged between $1.60 and $14.27. That is the range of closing prices, not intraday highs and lows.
Has NXTC moved like this before?
Yes — we have 3 significant moves on record for NXTC, each at least 15% on heavy volume. They are listed with their dates above, including whether any news could be sourced for each one.
See it in context
NXTC opened +5.5% versus the prior close, then finished +11.0% from its open, on 1.4M shares traded.
Against the whole market that day, 38.2% of US stocks closed higher (median move -0.2%) — so NXTC rose even as most stocks fell. See the full market recap →
More movers: today's biggest gainers · today's biggest gap-ups · all screeners · why other stocks are moving
Learn the basics: how to read a chart · what volume means · grade NXTC’s chart with the AI reader →